secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001213900-24-096243
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics reports Q3 2024 net loss of $11.2M; cash $81.5M; pipeline on track
--------------------------------------------------------------------------------

- Net loss $11.2M ($0.50 per share) vs $9.9M ($0.87) in Q3 2023; no revenue.
- Cash, equivalents, and investments $81.5M as of Sept 30; sufficient to fund operations into 2026.
- R&D expenses $8.1M; G&A $4.3M; stock-based comp $0.9M.
- On track to report interim 6-month data from TARA-002 in NMIBC ADVANCED-2 trial in 4Q 2024.
- FDA Fast Track granted for IV Choline Chloride; THRIVE-3 first patient dosing expected in 1Q 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/0001213900-24-096243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea0219258-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-096243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer